Alzheimer's disease: Synapses gone cold

Molecular Neurodegeneration

Volumn 6, Issue 1, 2011, Pages

  Koffie, Robert M ^a,b   Hyman, Bradley T ^a   Spires Jones, Tara L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Building C 2   (United States)

Author keywords

Alzheimer's disease; amyloid beta; cognitive decline; long term depression; long term potentiation; synapse loss

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; BRAIN ELECTROPHYSIOLOGY; COGNITIVE DEFECT; HUMAN; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MEMORY; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; REVIEW; SYNAPSE; SYNAPTIC INHIBITION;

ANIMALIA;

EID: 80052027401     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-6-63     Document Type: Review

References (142)

1. Ubereine eigenartige Erkrankung der Hirnrinde. Alzheimer A, Allgemeine Zeitschrift fur Psychiatrie und Psychisch-Gerichtliche Medizin 1907 64 146 148
2. A century of Alzheimer's disease. Goedert M, Spillantini MG, Science 2006 314 5800 777 781 10.1126/science.1132814 17082447 (Pubitemid 44706636)
3. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA, Arch Neurol 2003 60 8 1119 1122 10.1001/archneur.60.8.1119 12925369 (Pubitemid 36975801)
4. -2011 Alzheimer's disease facts and figures. Alzheimer's A, Thies W, Bleiler L, Alzheimers Dement 2011 7 2 208 244 21414557
5. Alzheimer's disease: the challenge of the second century. Holtzman DM, Morris JC, Goate AM, Sci Transl Med 2011 3 77 77sr71
6. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Hardy J, Selkoe DJ, Science 2002 297 5580 353 356 10.1126/science.1072994 12130773 (Pubitemid 34790756)
7. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG, Science 2003 300 5618 486 489 10.1126/science.1079469 12702875 (Pubitemid 36444329)
8. Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Lansbury PT Jr, Proc Natl Acad Sci USA 1999 96 7 3342 3344 10.1073/pnas.96.7.3342 10097040 (Pubitemid 29168913)
9. In pursuit of the molecular structure of amyloid plaque: new technology provides unexpected and critical information. Lansbury PT Jr, Biochemistry 1992 31 30 6865 6870 10.1021/bi00145a001 1637821
10. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Tanzi RE, Bertram L, Cell 2005 120 4 545 555 10.1016/j.cell.2005. 02.008 15734686 (Pubitemid 40269768)
11. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC, Butler AC, Ann Neurol 1998 43 3 380 383 10.1002/ana.410430316 9506555 (Pubitemid 28113601)
12. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M, et al. Nat Genet 2006 38 1 24 26 10.1038/ng1718 16369530 (Pubitemid 43011878)
13. The genetics of Alzheimer disease: back to the future. Bertram L, Lill CM, Tanzi RE, Neuron 2010 68 2 270 281 10.1016/j.neuron.2010.10.013 20955934
14. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Bertram L, Tanzi RE, Nat Rev Neurosci 2008 9 10 768 778 10.1038/nrn2494 18802446
15. Direct and potent regulation of gamma-secretase by its lipid microenvironment. Osenkowski P, Ye W, Wang R, Wolfe MS, Selkoe DJ, J Biol Chem 2008 283 33 22529 22540 10.1074/jbc.M801925200 18539594
16. In search of gamma-secretase: presenilin at the cutting edge. Selkoe DJ, Wolfe MS, Proc Natl Acad Sci USA 2000 97 11 5690 5692 10.1073/pnas.97.11.5690 10823929 (Pubitemid 30367457)
17. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ, Nature 1999 398 6727 513 517 10.1038/19077 10206644 (Pubitemid 29177490)
18. Neurotoxicity and physicochemical properties of Abeta mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease. Murakami K, Irie K, Morimoto A, Ohigashi H, Shindo M, Nagao M, Shimizu T, Shirasawa T, J Biol Chem 2003 278 46 46179 46187 10.1074/jbc.M301874200 12944403 (Pubitemid 37432769)
19. Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation. Tsubuki S, Takaki Y, Saido TC, Lancet 2003 361 9373 1957 1958 10.1016/S0140-6736(03)13555-6 12801742 (Pubitemid 36694587)
20. Alzheimer-type neuropathology in transgenic mice overexpressing V717F [beta]-amyloid precursor protein. Games D, Adams D, Alessandrini R, Barbour R, Borthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, et al. Nature 1995 373 6514 523 527 10.1038/373523a0 7845465
21. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L, J Neurosci 2000 20 11 4050 4058 10818140 (Pubitemid 30365675)
22. A specific amyloid-beta protein assembly in the brain impairs memory. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH, Nature 2006 440 7082 352 357 10.1038/nature04533 16541076
23. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM, Neuron 2004 43 3 321 332 10.1016/j.neuron. 2004.07.003 15294141 (Pubitemid 39061125)
24. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Lemere CA, Masliah E, Nat Rev Neurol 2010 6 2 108 119 10.1038/nrneurol.2009.219 20140000
25. Alzheimer's disease is a synaptic failure. Selkoe DJ, Science 2002 298 5594 789 791 10.1126/science.1074069 12399581 (Pubitemid 35231524)
26. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW, Morris JC, Neurology 2001 56 1 127 129 11148253 (Pubitemid 32059669)
27. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. DeKosky ST, Scheff SW, Ann Neurol 1990 27 5 457 464 10.1002/ana.410270502 2360787 (Pubitemid 20149963)
28. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R, Ann Neurol 1991 30 4 572 580 10.1002/ana.410300410 1789684
29. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. Davies CA, Mann DM, Sumpter PQ, Yates PO, J Neurol Sci 1987 78 2 151 164 10.1016/0022-510X(87)90057-8 3572454 (Pubitemid 17031709)
30. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ, Neurology 2007 68 18 1501 1508 10.1212/01.wnl.0000260698.46517.8f 17470753 (Pubitemid 46685921)
31. Structural correlates of cognition in dementia: quantification and assessment of synapse change. DeKosky ST, Scheff SW, Styren SD, Neurodegeneration 1996 5 4 417 421 10.1006/neur.1996.0056 9117556 (Pubitemid 27077903)
32. Synaptic slaughter in Alzheimer's disease. Coleman PD, Yao PJ, Neurobiol Aging 2003 24 8 1023 1027 10.1016/j.neurobiolaging.2003.09.001 14643374 (Pubitemid 37487880)
33. Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. Lanz TA, Carter DB, Merchant KM, Neurobiol Dis 2003 13 3 246 253 10.1016/S0969-9961(03)00079-2 12901839 (Pubitemid 36937206)
34. Dendrite and dendritic spine alterations in Alzheimer models. Moolman DL, Vitolo OV, Vonsattel JP, Shelanski ML, J Neurocytol 2004 33 3 377 387 15475691 (Pubitemid 39361303)
35. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Tsai J, Grutzendler J, Duff K, Gan WB, Nat Neurosci 2004 7 11 1181 1183 10.1038/nn1335 15475950 (Pubitemid 39426234)
36. Nature, nurture and neurology: gene-environment interactions in neurodegenerative disease. FEBS Anniversary Prize Lecture delivered on 27 June 2004 at the 29th FEBS Congress in Warsaw. Spires TL, Hannan AJ, FEBS J 2005 272 10 2347 2361 10.1111/j.1742-4658.2005.04677.x 15885086 (Pubitemid 40705057)
37. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, et al. Proc Natl Acad Sci USA 2009 106 10 4012 4017 10.1073/pnas.0811698106 19228947
38. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ, J Neurosci 1999 19 20 8876 8884 10516307 (Pubitemid 30226709)
39. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, Benedek GB, Selkoe DJ, Teplow DB, J Biol Chem 1999 274 36 25945 25952 10.1074/jbc.274.36.25945 10464339 (Pubitemid 29418632)
40. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Harper JD, Wong SS, Lieber CM, Lansbury PT, Chem Biol 1997 4 2 119 125 10.1016/S1074-5521(97)90255-6 9190286 (Pubitemid 27161750)
41. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, et al. Proc Natl Acad Sci USA 1998 95 11 6448 6453 10.1073/pnas.95.11.6448 9600986 (Pubitemid 28249033)
42. Neurodegenerative disease: amyloid pores from pathogenic mutations. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr, Nature 2002 418 6895 291 12124614 (Pubitemid 34790672)
43. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ, Biochemistry 2000 39 35 10831 10839 10.1021/bi001048s 10978169
44. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ, Nature 2002 416 6880 535 539 10.1038/416535a 11932745 (Pubitemid 34288854)
45. A specific amyloid-[beta] protein assembly in the brain impairs memory. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH, 2006 440 7082 352 357
46. Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging. Enya M, Morishima-Kawashima M, Yoshimura M, Shinkai Y, Kusui K, Khan K, Games D, Schenk D, Sugihara S, Yamaguchi H, et al. Am J Pathol 1999 154 1 271 279 10.1016/S0002-9440(10)65273-X 9916941 (Pubitemid 29031634)
47. Presence of sodium dodecyl sulfate-stable amyloid beta-protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation. Funato H, Enya M, Yoshimura M, Morishima-Kawashima M, Ihara Y, Am J Pathol 1999 155 1 23 28 10.1016/S0002-9440(10)65094-8 10393832 (Pubitemid 29318698)
48. Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ, Woods AS, Cotter RJ, Tuohy JM, Krafft GA, et al. J Biol Chem 1996 271 34 20631 20635 10.1074/jbc.271.34.20631 8702810 (Pubitemid 26281842)
49. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, et al. Brain Res 2002 924 2 133 140 10.1016/S0006-8993(01)03058-X 11750898 (Pubitemid 34102301)
50. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ, J Physiol 2006 572 Pt 2 477 492 16469784
51. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL, J Neurosci 2007 27 11 2866 2875 10.1523/JNEUROSCI.4970-06.2007 17360908 (Pubitemid 46438992)
52. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, et al. Nat Med 2008 14 8 837 842 10.1038/nm1782 18568035
53. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. Townsend M, Mehta T, Selkoe DJ, J Biol Chem 2007 282 46 33305 33312 10.1074/jbc.M610390200 17855343 (Pubitemid 350159548)
54. Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. Walsh DM, Townsend M, Podlisny MB, Shankar GM, Fadeeva JV, El Agnaf O, Hartley DM, Selkoe DJ, J Neurosci 2005 25 10 2455 2462 10.1523/JNEUROSCI.4391-04.2005 15758153 (Pubitemid 40365155)
55. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D, Neuron 2009 62 6 788 801 10.1016/j.neuron.2009.05.012 19555648
56. Use-dependent effects of amyloidogenic fragments of (beta)-amyloid precursor protein on synaptic plasticity in rat hippocampus in vivo. Kim JH, Anwyl R, Suh YH, Djamgoz MB, Rowan MJ, J Neurosci 2001 21 4 1327 1333 11160403 (Pubitemid 32128777)
57. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Palop JJ, Mucke L, Nat Neurosci 2010 13 7 812 818 10.1038/nn.2583 20581818
58. Long-term depression: a cascade of induction and expression mechanisms. Kemp N, Bashir ZI, Prog Neurobiol 2001 65 4 339 365 10.1016/S0301-0082(01)00013- 2 11527572 (Pubitemid 32781668)
59. Long-term potentiation is mediated by multiple kinase cascades involving CaMKII or either PKA or p42/44 MAPK in the adult rat dentate gyrus in vitro. Wu J, Rowan MJ, Anwyl R, J Neurophysiol 2006 95 6 3519 3527 10.1152/jn.01235.2005 16709720 (Pubitemid 43846161)
60. Long-term depression of NMDA receptor-mediated synaptic transmission is dependent on activation of metabotropic glutamate receptors and is altered to long-term potentiation by low intracellular calcium buffering. Harney SC, Rowan M, Anwyl R, J Neurosci 2006 26 4 1128 1132 10.1523/JNEUROSCI.2753-05.2006 16436598 (Pubitemid 43237044)
61. Induction and expression mechanisms of postsynaptic NMDA receptor-independent homosynaptic long-term depression. Anwyl R, Prog Neurobiol 2006 78 1 17 37 10.1016/j.pneurobio.2005.12.001 16423442 (Pubitemid 43248710)
62. Synaptic plasticity: multiple forms, functions, and mechanisms. Citri A, Malenka RC, Neuropsychopharmacology 2008 33 1 18 41 10.1038/sj.npp.1301559 17728696 (Pubitemid 350191314)
63. Long-term synaptic plasticity in hippocampal interneurons. Kullmann DM, Lamsa KP, Nat Rev Neurosci 2007 8 9 687 699 10.1038/nrn2207 17704811 (Pubitemid 47283146)
64. Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Liu L, Wong TP, Pozza MF, Lingenhoehl K, Wang Y, Sheng M, Auberson YP, Wang YT, Science 2004 304 5673 1021 1024 10.1126/science.1096615 15143284 (Pubitemid 38638102)
65. Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. Sheng M, Cummings J, Roldan LA, Jan YN, Jan LY, Nature 1994 368 6467 144 147 10.1038/368144a0 8139656 (Pubitemid 24101524)
66. Subtype-dependence of NMDA receptor channel open probability. Chen N, Luo T, Raymond LA, J Neurosci 1999 19 16 6844 6854 10436042 (Pubitemid 29380113)
67. Importance of the intracellular domain of NR2 subunits for NMDA receptor function in vivo. Sprengel R, Suchanek B, Amico C, Brusa R, Burnashev N, Rozov A, Hvalby O, Jensen V, Paulsen O, Andersen P, et al. Cell 1998 92 2 279 289 10.1016/S0092-8674(00)80921-6 9458051 (Pubitemid 28073050)
68. Ligand-gated ion channel interactions with cytoskeletal and signaling proteins. Sheng M, Pak DT, Annu Rev Physiol 2000 62 755 778 10.1146/annurev. physiol.62.1.755 10845110 (Pubitemid 30618281)
69. Structural basis of long-term potentiation in single dendritic spines. Matsuzaki M, Honkura N, Ellis-Davies GC, Kasai H, Nature 2004 429 6993 761 766 10.1038/nature02617 15190253 (Pubitemid 38833127)
70. Bidirectional activity-dependent morphological plasticity in hippocampal neurons. Nagerl UV, Eberhorn N, Cambridge SB, Bonhoeffer T, Neuron 2004 44 5 759 767 10.1016/j.neuron.2004.11.016 15572108 (Pubitemid 39575630)
71. Shrinkage of dendritic spines associated with long-term depression of hippocampal synapses. Zhou Q, Homma KJ, Poo MM, Neuron 2004 44 5 749 757 10.1016/j.neuron.2004.11.011 15572107 (Pubitemid 39575629)
72. Synapse elimination accompanies functional plasticity in hippocampal neurons. Bastrikova N, Gardner GA, Reece JM, Jeromin A, Dudek SM, Proc Natl Acad Sci USA 2008 105 8 3123 3127 10.1073/pnas.0800027105 18287055 (Pubitemid 351723678)
73. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R, J Neurosci 2004 24 13 3370 3378 10.1523/JNEUROSCI.1633-03.2004 15056716 (Pubitemid 38451902)
74. Divergent pathways mediate spine alterations and cell death induced by amyloid-beta, wild-type tau, and R406W tau. Tackenberg C, Brandt R, J Neurosci 2009 29 46 14439 14450 10.1523/JNEUROSCI.3590-09.2009 19923278
75. Caspase-3 activation via mitochondria is required for long-term depression and AMPA receptor internalization. Li Z, Jo J, Jia JM, Lo SC, Whitcomb DJ, Jiao S, Cho K, Sheng M, Cell 2010 141 5 859 871 10.1016/j.cell.2010.03.053 20510932
76. Distinct effects of cAMP and mitogenic signals on CREB-binding protein recruitment impart specificity to target gene activation via CREB. Mayr BM, Canettieri G, Montminy MR, Proc Natl Acad Sci USA 2001 98 19 10936 10941 10.1073/pnas.191152098 11535812 (Pubitemid 32878722)
77. Transcriptional regulation by the phosphorylation-dependent factor CREB. Mayr B, Montminy M, Nat Rev Mol Cell Biol 2001 2 8 599 609 10.1038/35085068 11483993 (Pubitemid 33674011)
78. Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Cummings BJ, Pike CJ, Shankle R, Cotman CW, Neurobiol Aging 1996 17 6 921 933 10.1016/S0197-4580(96)00170-4 9363804 (Pubitemid 27022746)
79. Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression. Mulkey RM, Endo S, Shenolikar S, Malenka RC, Nature 1994 369 6480 486 488 10.1038/369486a0 7515479
80. beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB, J Biol Chem 2000 275 8 5626 5632 10.1074/jbc.275.8.5626 10681545 (Pubitemid 30115201)
81. Regulation of NMDA receptor trafficking by amyloid-beta. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, et al. Nat Neurosci 2005 8 8 1051 1058 10.1038/nn1503 16025111 (Pubitemid 41061516)
82. Expression mechanisms underlying NMDA receptor-dependent long-term potentiation. Nicoll RA, Malenka RC, Ann N Y Acad Sci 1999 868 515 525 10.1111/j.1749-6632.1999.tb11320.x 10414328 (Pubitemid 29281159)
83. Abeta(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3beta. Jo J, Whitcomb DJ, Olsen KM, Kerrigan TL, Lo SC, Bru-Mercier G, Dickinson B, Scullion S, Sheng M, Collingridge G, et al. Nat Neurosci 2011 14 5 545 547 10.1038/nn.2785 21441921
84. Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. D'Amelio M, Cavallucci V, Middei S, Marchetti C, Pacioni S, Ferri A, Diamantini A, De Zio D, Carrara P, Battistini L, et al. Nat Neurosci 2011 14 1 69 76 10.1038/nn.2709 21151119
85. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R, Neuron 2006 52 5 831 843 10.1016/j.neuron.2006.10.035 17145504 (Pubitemid 44828454)
86. Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling. Abdul HM, Sama MA, Furman JL, Mathis DM, Beckett TL, Weidner AM, Patel ES, Baig I, Murphy MP, LeVine H, et al. J Neurosci 2009 29 41 12957 12969 10.1523/JNEUROSCI.1064-09.2009 19828810
87. Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Kuchibhotla KV, Goldman ST, Lattarulo CR, Wu HY, Hyman BT, Bacskai BJ, Neuron 2008 59 2 214 225 10.1016/j.neuron.2008.06.008 18667150 (Pubitemid 352033686)
88. A CaMKII/calcineurin switch controls the direction of Ca(2+)-dependent growth cone guidance. Wen Z, Guirland C, Ming GL, Zheng JQ, Neuron 2004 43 6 835 846 10.1016/j.neuron.2004.08.037 15363394 (Pubitemid 39215014)
89. Role of phosphorylation in regulation of the assembly of endocytic coat complexes. Slepnev VI, Ochoa GC, Butler MH, Grabs D, De Camilli P, Science 1998 281 5378 821 824 9694653 (Pubitemid 28376042)
90. Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice. Dineley KT, Hogan D, Zhang WR, Taglialatela G, Neurobiol Learn Mem 2007 88 2 217 224 10.1016/j.nlm.2007.03.010 17521929 (Pubitemid 47223751)
91. Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. Wu HY, Hudry E, Hashimoto T, Kuchibhotla K, Rozkalne A, Fan Z, Spires-Jones T, Xie H, Arbel-Ornath M, Grosskreutz CL, et al. J Neurosci 2010 30 7 2636 2649 10.1523/JNEUROSCI.4456-09.2010 20164348
92. Calcineurin inhibition with FK506 ameliorates dendritic spine density deficits in plaque-bearing Alzheimer model mice. Rozkalne A, Hyman BT, Spires-Jones TL, Neurobiol Dis 2011 41 3 650 654 10.1016/j.nbd.2010.11.014 21134458
93. Calcineurin inhibition with systemic FK506 treatment increases dendritic branching and dendritic spine density in healthy adult mouse brain. Spires-Jones TL, Kay K, Matsouka R, Rozkalne A, Betensky RA, Hyman BT, Neurosci Lett 2011 487 3 260 263 10.1016/j.neulet.2010.10.033 20970476
94. Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model. Zhang Y, Kurup P, Xu J, Carty N, Fernandez SM, Nygaard HB, Pittenger C, Greengard P, Strittmatter SM, Nairn AC, et al. Proc Natl Acad Sci USA 2010 107 44 19014 19019 10.1073/pnas.1013543107 20956308
95. The role of STEP in Alzheimer's disease. Kurup P, Zhang Y, Venkitaramani DV, Xu J, Lombroso PJ, Channels (Austin) 2010 4 5 347 350
96. Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61. Kurup P, Zhang Y, Xu J, Venkitaramani DV, Haroutunian V, Greengard P, Nairn AC, Lombroso PJ, J Neurosci 2010 30 17 5948 5957 10.1523/JNEUROSCI.0157-10.2010 20427654
97. Modulation of NMDA receptor-dependent calcium influx and gene expression through EphB receptors. Takasu MA, Dalva MB, Zigmond RE, Greenberg ME, Science 2002 295 5554 491 495 10.1126/science.1065983 11799243 (Pubitemid 34101638)
98. The receptor tyrosine kinase EphB2 regulates NMDA-dependent synaptic function. Henderson JT, Georgiou J, Jia Z, Robertson J, Elowe S, Roder JC, Pawson T, Neuron 2001 32 6 1041 1056 10.1016/S0896-6273(01)00553-0 11754836 (Pubitemid 34075395)
99. EphB receptors interact with NMDA receptors and regulate excitatory synapse formation. Dalva MB, Takasu MA, Lin MZ, Shamah SM, Hu L, Gale NW, Greenberg ME, Cell 2000 103 6 945 956 10.1016/S0092-8674(00)00197-5 11136979
100. Bidirectional signaling of ErbB and Eph receptors at synapses. Chen Y, Fu AK, Ip NY, Neuron Glia Biol 2008 4 3 211 221 10.1017/S1740925X09990287 19785921
101. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Cisse M, Halabisky B, Harris J, Devidze N, Dubal DB, Sun B, Orr A, Lotz G, Kim DH, Hamto P, et al. Nature 2011 469 7328 47 52 10.1038/nature09635 21113149
102. Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease. Simon AM, de Maturana RL, Ricobaraza A, Escribano L, Schiapparelli L, Cuadrado-Tejedor M, Perez-Mediavilla A, Avila J, Del Rio J, Frechilla D, J Alzheimers Dis 2009 17 4 773 786 19542617
103. Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Vitolo OV, Sant'Angelo A, Costanzo V, Battaglia F, Arancio O, Shelanski M, Proc Natl Acad Sci USA 2002 99 20 13217 13221 10.1073/pnas.172504199 12244210
104. Soluble A{beta} Oligomers Inhibit Long-Term Potentiation through a Mechanism Involving Excessive Activation of Extrasynaptic NR2B-Containing NMDA Receptors. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ, J Neurosci 2011 31 18 6627 6638 10.1523/JNEUROSCI.0203-11.2011 21543591
105. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Selkoe DJ, Behav Brain Res 2008 192 1 106 113 10.1016/j.bbr.2008. 02.016 18359102
106. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT, J Neurosci 2005 25 31 7278 7287 10.1523/JNEUROSCI.1879-05.2005 16079410 (Pubitemid 41113944)
107. A single dose of passive immunotherapy has extended benefits on synapses and neurites in an Alzheimer's disease mouse model. Rozkalne A, Spires-Jones TL, Stern EA, Hyman BT, Brain Res 2009 1280 178 185 19465012
108. Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease. Spires-Jones TL, Mielke ML, Rozkalne A, Meyer-Luehmann M, de Calignon A, Bacskai BJ, Schenk D, Hyman BT, Neurobiol Dis 2009 33 2 213 220 10.1016/j.nbd.2008.10.011 19028582
109. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L, Proc Natl Acad Sci USA 1999 96 6 3228 3233 10.1073/pnas.96.6.3228 10077666 (Pubitemid 29148873)
110. APP processing and synaptic function. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R, Neuron 2003 37 6 925 937 10.1016/S0896-6273(03)00124-7 12670422 (Pubitemid 36398299)
111. Down's syndrome and Alzheimer's disease: dendritic spine counts in the hippocampus. Ferrer I, Gullotta F, Acta Neuropathol 1990 79 6 680 685 10.1007/BF00294247 2141748 (Pubitemid 20170346)
112. Neurodegenerative stimuli induce persistent ADF/cofilin-actin rods that disrupt distal neurite function. Minamide LS, Striegl AM, Boyle JA, Meberg PJ, Bamburg JR, Nat Cell Biol 2000 2 9 628 636 10.1038/35023579 10980704
113. Delayed behavioral effects following intrahippocampal injection of aggregated A beta (1-42). O'Hare E, Weldon DT, Mantyh PW, Ghilardi JR, Finke MP, Kuskowski MA, Maggio JE, Shephard RA, Cleary J, Brain Res 1999 815 1 1 10 10.1016/S0006-8993(98)01002-6 9974116 (Pubitemid 29225218)
114. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH, Nat Neurosci 2005 8 1 79 84 10.1038/nn1372 15608634 (Pubitemid 41236735)
115. Beta-amyloid(1-40) effects on behavior and memory. Cleary J, Hittner JM, Semotuk M, Mantyh P, O'Hare E, Brain Res 1995 682 1-2 69 74 10.1016/0006- 8993(95)00323-I 7552329
116. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH, J Neurosci 2002 22 15 6331 6335 12151510 (Pubitemid 35386387)
117. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, et al. Nat Neurosci 2002 5 5 452 457 11941374 (Pubitemid 34454251)
118. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, et al. Nat Med 2005 11 5 556 561 10.1038/nm1234 15834427 (Pubitemid 40685979)
119. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, Phinney AL, Darabie AA, Cousins JE, French JE, Lan MF, et al. Nat Med 2006 12 7 801 808 10.1038/nm1423 16767098 (Pubitemid 44050070)
120. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL, Proc Natl Acad Sci USA 2003 100 18 10417 10422 10.1073/pnas.1834302100 12925731 (Pubitemid 37071893)
121. Endogenous amyloid-beta is necessary for hippocampal synaptic plasticity and memory. Puzzo D, Privitera L, Fa M, Staniszewski A, Hashimoto G, Aziz F, Sakurai M, Ribe EM, Troy CM, Mercken M, et al. Ann Neurol 2011 69 5 819 830 10.1002/ana.22313 21472769
122. Picomolar Amyloid-{beta} Positively Modulates Synaptic Plasticity and Memory in Hippocampus. 10.1523/JNEUROSCI.2692-08.2008. Puzzo D, Privitera L, Leznik E, Fa M, Staniszewski A, Palmeri A, Arancio O, J Neurosci 2008 28 53 14537 14545 10.1523/JNEUROSCI.2692-08.2008 19118188
123. Beta-amyloid modulation of synaptic transmission and plasticity. Venkitaramani DV, Chin J, Netzer WJ, Gouras GK, Lesne S, Malinow R, Lombroso PJ, J Neurosci 2007 27 44 11832 11837 10.1523/JNEUROSCI.3478-07.2007 17978019 (Pubitemid 350072092)
124. Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. Abramov E, Dolev I, Fogel H, Ciccotosto GD, Ruff E, Slutsky I, Nat Neurosci 2009 12 12 1567 1576 10.1038/nn.2433 19935655
125. Array tomography: production of arrays. Micheva KD, O'Rourke N, Busse B, Smith SJ, Cold Spring Harb Protoc 2010 2010 11 pdb prot 5524
126. Array tomography: a new tool for imaging the molecular architecture and ultrastructure of neural circuits. Micheva KD, Smith SJ, Neuron 2007 55 1 25 36 10.1016/j.neuron.2007.06.014 17610815 (Pubitemid 46990817)
127. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, Lee VM, J Biol Chem 2006 281 7 4292 4299 10.1074/jbc.M511018200 16361260 (Pubitemid 43847859)
128. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM, Neuron 2005 48 6 913 922 10.1016/j.neuron.2005.10.028 16364896 (Pubitemid 41814696)
129. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, Holtzman DM, Neuron 2008 58 1 42 51 10.1016/j.neuron.2008.02.003 18400162 (Pubitemid 351467029)
130. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, et al. J Neurosci 2003 23 26 8844 8853 14523085 (Pubitemid 37210896)
131. Amyloid precursor protein overexpression depresses excitatory
132. Synapse formation and function is modulated by the amyloid precursor protein. Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J, J Neurosci 2006 26 27 7212 7221 10.1523/JNEUROSCI.1450-06.2006 16822978
133. High ability of apolipoprotein E4 to stabilize amyloid-{beta} peptide oligomers, the pathological entities responsible for Alzheimer's disease. Cerf E, Gustot A, Goormaghtigh E, Ruysschaert JM, Raussens V, FASEB J 2011 25 5 1585 1595 10.1096/fj.10-175976 21266538
134. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM, Nature 2009 457 7233 1128 1132 10.1038/nature07761 19242475
135. Alzheimer's Disease Brain-Derived Amyloid-{beta}-Mediated Inhibition of LTP In Vivo Is Prevented by Immunotargeting Cellular Prion Protein. Barry AE, Klyubin I, Mc Donald JM, Mably AJ, Farrell MA, Scott M, Walsh DM, Rowan MJ, J Neurosci 2011 31 20 7259 7263 10.1523/JNEUROSCI.6500-10.2011 21593310
136. The prion protein as a receptor for amyloid-beta. Kessels HW, Nguyen LN, Nabavi S, Malinow R, Nature 2010 466 7308 3 4; discussion E4-5 10.1038/nature09217 20703260
137. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Balducci C, Beeg M, Stravalaci M, Bastone A, Sclip A, Biasini E, Tapella L, Colombo L, Manzoni C, Borsello T, et al. Proc Natl Acad Sci USA 2010 107 5 2295 2300 10.1073/pnas.0911829107 20133875
138. Prion protein and Abeta-related synaptic toxicity impairment. Calella AM, Farinelli M, Nuvolone M, Mirante O, Moos R, Falsig J, Mansuy IM, Aguzzi A, EMBO Mol Med 2010 2 8 306 314 10.1002/emmm.201000082 20665634
139. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, Triller A, Neuron 2010 66 5 739 754 10.1016/j.neuron.2010.04.029 20547131
140. Amyloid-Dependent and Amyloid-Independent Stages of Alzheimer Disease. Hyman BT, Arch Neurol 2011
141. Are Tangles as Toxic as They Look? Spires-Jones TL, Kopeikina KJ, Koffie RM, de Calignon A, Hyman BT, J Mol Neurosci 2011
142. Monitoring protein aggregation and toxicity in Alzheimer's disease mouse models using in vivo imaging. Spires-Jones TL, de Calignon A, Meyer-Luehmann M, Bacskai BJ, Hyman BT, Methods 2011 53 3 201 207 10.1016/j.ymeth.2010.12.009 21163350